Drug Trial Radar · NCT04113616
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)
Last checked: Nov 19, 2026Latest source record: Mar 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
70
Actual
Start
Sep 25, 2019
Primary completion
Sep 27, 2023
Study completion Sep 27, 2023
Sponsor
- Lead sponsor
- Kartos Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 3, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, when administered alone and in combination with low-dose cytarabine (LDAC) or Decitabine for the treatment of adults with Acute Myeloid Leukemia (AML) and AML secondary to myeloproliferative neoplasms (MPN). Participants must be relapsed/refractory (having failed prior therapy) and will be assigned to receive monotherapy (KRT-232 alone) or combination therapy (KRT-232 with LDAC or KRT-232 with Decitabine).
Conditions
- Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)
Interventions
KRT-232Drug
KRT-232 is an experimental MDM2 inhibitor anti-cancer drug taken by mouth.
CytarabineDrug
Cytarabine is an anti-cancer chemotherapy drug taken via injection.
DecitabineDrug
Decitabine is an anti-cancer chemotherapy drug taken via injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: To determine KRT-232 recommended phase 2 dose (RP2D)Time frame: 28 Days
- Part B: To determine the RP2D of KRT-232Time frame: 2 years after last patient enrolled
Locations
59 sites in 12 countries. Site status is shown where the registry gives one.
University of Chicago
Chicago, Illinois
University of Maryland Medical Center
Baltimore, Maryland
Mount Sinai
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Weill Cornell
New York, New York
The Ohio State University
Columbus, Ohio
Oregon Health and Science University
Portland, Oregon
MD Anderson Cancer Center
Houston, Texas
Monash Health
Clayton, Australia
St. George Hospital
Kogarah, Australia
Royal Perth Hospital
Perth, Australia
Calvary Mater Newcastle Hospital
Waratah, Australia
Perth Blood Institute
West Perth, Australia
Institut Jules Bordet
Anderlecht, Belgium
Cliniques universitaires Saint-Luc
Brussels, Belgium
UZ Gent
Ghent, Belgium
Centre Hospitalier (CH) Jolimont
Haine-Saint-Paul, Belgium
AZ Turnhout
Turnhout, Belgium
Centre Hospitalier Universitaire (CHU) de Bordeaux
Bordeaux, France
Institut Paoli Calmettes
Marseille, France
Centre Hospitalier Universitaire (CHU) de Nice
Nice, France
Hôpital Saint-Louis
Paris, France
Universitätsklinikum Halle
Halle, Germany
Universitätsklinikum Hamburg-Eppendorf
Hamburg, Germany
University Hospital Jena
Jena, Germany
Universitätsklinikum Leipzig
Leipzig, Germany
Universitaetsklinikum Schleswig-Holstein
Lübeck, Germany
Semmelweis Egyetem
Budapest, Hungary
Del-Pesti Centrumkorhaz Orszagos Hematologiai es Infektologi
Budapest, Hungary
szabolcs-szatmár-bereg megyei kórházak és egyetemi oktatókórház Jósa András Oktatókórház
Debrecen, Hungary
Somogy Megyei KAposi Mor Oktato Korhaz
Kaposvár, Hungary
Rambam Health Care Campus
Haifa, Israel
Hadassah Medical Center Ein Kerem
Jerusalem, Israel
The Chaim Sheba Medical Center
Ramat Gan, Israel
Tel-Aviv Sourasky Medical Center
Tel Aviv, Israel
Assaf Harofeh Medical Center AHMC
Tel Aviv, Israel
AOU Policlinico S.Orsola-Malpighi
Bologna, Italy
AORMN Hospital Hematology and BMT Center
Pesaro, Italy
AOUS Le Scotte
Siena, Italy
Universitaria Maggiore della Carità Novara
Novara, Piedmont, Italy
Showing 40 of 59 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.